SCHEMBL19348178

SCHEMBL19348178

CONC(=O)c1cc(I)cc(C)c1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.45
PKM P14618 1/20 0.45
ALDH1A1 P00352 5/20 0.41
CNR1 P21554 5/20 0.38
CNR2 P34972 5/20 0.38
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
MAPK1 P28482 2/20 0.37
DRD2 P14416 1/20 0.37
MAPT P10636 3/20 0.36
HTT P42858 2/20 0.36
HSD17B10 Q99714 2/20 0.36
GAA P10253 2/20 0.36
MAP2K1 Q02750 1/20 0.36
ALOX15 P16050 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30810326 0.81 KDM4E (0.44) KDM4EPKMALDH1A1LMNASMN1; SMN2
SCHEMBL4878432 0.81 KDM4E (0.44) KDM4EPKMALDH1A1LMNASMN1; SMN2
SCHEMBL440813 0.80 HSD17B10 (0.47) KDM4EPKMALDH1A1LMNAMAPT
SCHEMBL4745038 0.75 KDM4E (0.37) KDM4EPKMALDH1A1CNR1CNR2
SCHEMBL4599330 0.72 ACHE (0.40) KDM4EALDH1A1SMN1; SMN2MAPK1MAPT
SCHEMBL29904965 0.69 KDM4E (0.49) KDM4EPKMALDH1A1SMN1; SMN2MAPK1
SCHEMBL25295693 0.68 KDM4E (0.47) KDM4EALDH1A1MAPTHSD17B10GAA
SCHEMBL8364052 0.68 HTT (0.47) KDM4EALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL19348131 0.68 KDM4E (0.31) KDM4EPKM
SCHEMBL19348241 0.68 KDM4E (0.31) KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170267667-A1 ALKENYLDIARYLMETHANES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR ANTI-HIV-1 CHEMOTHERAPY PURDUE RESEARCH FOUNDATION (US) 2017-09-21 US disclosed
US-20170267667-A1 ALKENYLDIARYLMETHANES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR ANTI-HIV-1 CHEMOTHERAPY PURDUE RESEARCH FOUNDATION (US) 2017-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267667-A1 ALKENYLDIARYLMETHANES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR ANTI-HIV-1 CHEMOTHERAPY TYMP, SAMHD1, TYMS KDM4E 1501/4885PKM 3683/4885ALDH1A1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.